

## Public Relations Newsroom

Where reporters connect with information.

[HOME](#)

[Novelty Lenses](#)

[Jazz CDs Debut](#)

[USP 797](#)

[BioScience](#)

[Compounding](#)

[Cleanrooms](#)

[CBSA Magazine](#)

[Protect DVDs & CDs](#)

[CONTACT](#)



PR Pharmaceuticals

### FORT COLLINS COMPANY MAKING ALL THE RIGHT MOVES

The Executive Team At A Company Called PR Pharmaceuticals (PRP) Has A Knack For Making The Right Moves.



That talent may soon reap huge benefits for millions of patients with diabetes and heart disease.

PRP is the result of a 1998 merger between Micrel Limited, an Arizona drug delivery company founded by PRP's CEO Steve Howe, and the Fort Collins based Wildlife Pharmaceuticals. Today PRP is a privately owned company that develops and manufactures innovative sustained release drug delivery technologies for human and animal health.

Howe says the decision to come to Colorado was easy. The Front Range, with its highly educated workforce, was ideally suited to a growing bioscience business. "We compete with the Bay Area and Boston for high level talent," says Howe. "The Colorado lifestyle and our lower cost of living are two big advantages in our favor."

With 55 employees and 25,000 square feet of state-of-the-art manufacturing facilities, PRP uses its proprietary controlled delivery technologies to make an existing drug work better. The idea is to develop its own product pipeline by bringing the discovery through Phase I or Phase II trials before licensing it out to a partner for commercialization. Howe says this model is the inverse of a typical drug discovery model.

"We already know the drug works, so the risk of late stage failure is minimal," he explains. "The risk is on the front end, not in Phase III."

Insulin is a good example. PRP's sustained delivery system can deliver a week's worth of insulin in one injection, allowing diabetics to go from daily use to weekly use. The company's InsuLAR(TM), is a weekly basal insulin injection expected to enter Phase I clinical trials next year. "This will be a revolutionary change for millions of patients," says Howe.

Another drug in development is PulmoLAR(TM), designed to be delivered every 30 days for patients with a pulmonary arterial hypertension - a dramatic shift in the way patients are currently treated. In April, the FDA granted orphan drug status to PulmoLAR(TM), an important step that recognizes the drug's potential based on encouraging results from pre-clinical studies.


PRP leverages its technologies to attract collaborations and partnerships. For example, a strategic alliance with one of the world's largest animal health companies, Merial, allows PRP to develop and manufacture new animal health products using PRP technologies, while Merial markets the products worldwide.

After investing more than \$25 million in its Fort Collins manufacturing infrastructure, PRP expects to see significant employee growth in the next several years. "We have a lot going on here," Howe says. "We have a great team and very little turnover."


Like its leadership, it seems that PRP is making all the right moves.

Note: This article is reprinted by permission from the Spring 2005 issue of The CBSA FOCUS newsletter. A link to a pdf of the entire issue is found below.

Also, the newsletter and prior feature on McKinley Medical are accessible in Adobe pdf format. If necessary, you can download the software free at the link found below.



Insulin microspheres - PRP's drug delivery systems may change the lives of millions of patients with diabetes.



Cross section of drug loaded microparticle.



Colorado BioScience  
ASSOCIATION

FOCUS is published quarterly by the Colorado BioScience Association, 1625 Broadway, Suite 950, Denver, CO 80202, with

[Link to a pdf of the Summer 2005 CBSA FOCUS Newsletter](#)

[Link to Spring 2005 Feature on McKinley Medical](#)

[Link to the Colorado BioScience Association Website](#)

[Link to the PR Pharmaceuticals Website](#)

[Contact PR Pharmaceuticals for more information](#)

additional offices at Fitzsimons Bioscience Park and Fort Collins. Denise Brown, executive director. Phone 303-592-4072. A link to the CBSA website is found on the right.

FOCUS is edited, written and produced by the Sage Public Relations Group in collaboration with Griff/SMC. Design and production is by New Moon Communications. For editorial comments and content ideas contact Jon Pushkin, editor, 303-733-3441; jon@pushkinpr.com.

Maggie Chamberlin Holben, owner of this website, has recently joined the Board of Directors for the Colorado BioScience Association and is making this page available to the CBSA to enhance media awareness of the association and its members.

[Free download of Adobe pdf Reader for your computer](#)

[Return to the top of the page](#)



[TPN Therapy - Case Study](#) [Infusion Therapy](#)

[Safe Handling](#)

[Page 14](#)

[Page 15](#)

[Page 16](#)

[Page 17](#)

[Page 18](#)

[Page 19](#)

[CBSA Digital Media Kit](#)